http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003191314-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2b9dc89cc4ba060cc73bbf0c90bbb78 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 2003-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d252c4939d22e6f15e22668693a0106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dadb1d9b697b8ec0a853eba1b56fa03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c2009e34d4f57dcac464356104b40aa |
| publicationDate | 2003-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003191314-A1 |
| titleOfInvention | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors |
| abstract | Compounds of formula (I): n n n wherein: n R 1 represents a substituent selected from: a hydrogen or halogen atom; a hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, pentafluoroethyl, C 1-4 alkyl, C 1-4 alkoxy, arylC 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkoxyC 1-4 alkyl, C 3-6 cycloalkylC 1-4 alkoxy, C 1-4 alkanoyl, C 1-4 alkoxycarbonyl, C 1-4 alkylsulfonyl, C 1-4 alkylsulfonyloxy, C 1-4 alkylsulfonylC 1-4 alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC 1-4 alkyl, C 1-4 alkylsulfonamido, C 1-4 alkylamido, C 1-4 alkylsulfonamidoC 1-4 alkyl, C 1-4 alkylamidoC 1-4 alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC 1-4 alkyl, arylcarboxamidoC 1-4 alkyl, aroyl, aroylC 1-4 alkyl, or arylC 1-4 alkanoyl group; a group R 3 OCO(CH 2 ) p , R 3 CON(R 4 )(CH 2 ) p , R 3 R 4 NCO(CH 2 ) p or R 3 R 4 NSO 2 (CH 2 ) p where each of R 3 and R 4 independently represents a hydrogen atom or a C 1-4 alkyl group or R 3 R 4 forms part of a C 3-6 azacyloalkane or C 3-6 (2-oxo)azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar 1 —Z, wherein Ar 1 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring and Z represents a bond, O, S , or CH 2 ; n R 2 represents a hydrogen atom or a C 1-4 alkyl group; n q is 1 or 2; n A represents a group of formula (a) or (b) n n n wherein n T, U, V and Y independently represent CH or a nitrogen atom; n R 5 is a group selected from: a hydrogen or halogen atom, cyano, C 1-4 alkyl or C 1-4 alkoxy group n s is 1 or 2. n Ar 2 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; and salts thereof. The compounds are useful for the treatment of conditions which require modulaton of a dopamine receptor such as schizophrenia. |
| priorityDate | 1998-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 266.